Gainers
- Regulus Therapeutics (NASDAQ:RGLS) shares moved upwards by 27.1% to $1.75 during Friday's after-market session. The market value of their outstanding shares is at $29.5 million.
- HTG Molecular Diagnostics (NASDAQ:HTGM) stock increased by 15.75% to $0.63. At the close, HTG Molecular Diagnostics's trading volume reached 708.4K shares. This is 525.5% of its average volume over the last 100 days. The market value of their outstanding shares is at $6.9 million.
- Aclarion (NASDAQ:ACON) shares moved upwards by 9.99% to $0.81. The company's market cap stands at $6.3 million.
- Moleculin Biotech (NASDAQ:MBRX) stock rose 8.27% to $1.44. The company's market cap stands at $41.2 million.
- Rubius Therapeutics (NASDAQ:RUBY) shares increased by 8.24% to $0.18. The company's market cap stands at $16.1 million.
- Anixa Biosciences (NASDAQ:ANIX) stock moved upwards by 6.19% to $4.8. The company's market cap stands at $147.1 million.
Losers
- Biolase (NASDAQ:BIOL) shares decreased by 9.3% to $0.65 during Friday's after-market session. The market value of their outstanding shares is at $4.6 million.
- Ambrx Biopharma (NYSE:AMAM) stock declined by 8.82% to $4.14. Ambrx Biopharma's trading volume hit 22.6 million shares by close, accounting for 23428.7% of its average volume over the last 100 days. The company's market cap stands at $159.8 million.
- Healthcare Triangle (NASDAQ:HCTI) shares decreased by 6.06% to $0.15. The company's market cap stands at $6.3 million.
- Adamis Pharmaceuticals (NASDAQ:ADMP) shares fell 5.8% to $0.17. The company's market cap stands at $26.0 million.
- NeuroBo Pharmaceuticals (NASDAQ:NRBO) shares fell 5.09% to $1.68. Trading volume for this security closed at 4.1 million, accounting for 136.0% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $10.9 million.
- Scopus BioPharma (NASDAQ:SCPS) stock decreased by 5.01% to $0.21. The market value of their outstanding shares is at $4.4 million. See Also:
This article was generated by Benzinga's automated content engine and reviewed by an editor.